To look at the current approach to aspirin challenge (drug provocation) and/or desensitization in patients who have a history of hypersensitive responses to it, particularly those with cardiovascular disease was the purpose of this study. According to the literature, individuals with coronary artery disease (CAD), even those suffering from an acute coronary syndrome, can safely undertake a low-dose aspirin challenge and/or desensitization. Flowcharts for aspirin challenge/desensitization treatments in patients with CAD and a history of aspirin hypersensitivity events have recently become accessible. Aspirin desensitization and continuous aspirin treatment are viable options for individuals with nonsteroidal anti-inflammatory drug-exacerbated respiratory disorders (NERD) who have poor control of their asthma or rhinosinusitis or who require frequent revision polypectomies.
Aspirin has been shown to decrease morbidity and death related to CAD. There is widespread agreement on the efficacy of aspirin in the secondary prevention of CAD. Aspirin desensitization is therefore required in individuals with CAD and a history of hypersensitive responses to it. Numerous studies have demonstrated the efficacy of aspirin desensitization and ongoing treatment in individuals with NERD. However, shared selection criteria for aspirin challenge/desensitization techniques, as well as simple and uniform methods, are required. Furthermore, preventive safety measures are still required to limit the possible hazards associated with these operations.
